These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 30731399)
1. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis. Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399 [TBL] [Abstract][Full Text] [Related]
2. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure. Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181 [TBL] [Abstract][Full Text] [Related]
3. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies. Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives. Zeinyeh W; Esvan YJ; Nauton L; Loaëc N; Meijer L; Théry V; Anizon F; Giraud F; Moreau P Bioorg Med Chem Lett; 2016 Sep; 26(17):4327-9. PubMed ID: 27469128 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I. Foucourt A; Hédou D; Dubouilh-Benard C; Désiré L; Casagrande AS; Leblond B; Loäec N; Meijer L; Besson T Molecules; 2014 Sep; 19(10):15546-71. PubMed ID: 25268714 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II. Foucourt A; Hédou D; Dubouilh-Benard C; Girard A; Taverne T; Casagrande AS; Désiré L; Leblond B; Besson T Molecules; 2014 Sep; 19(10):15411-39. PubMed ID: 25264830 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors. Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227 [TBL] [Abstract][Full Text] [Related]
9. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase. Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908 [TBL] [Abstract][Full Text] [Related]
10. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585 [TBL] [Abstract][Full Text] [Related]
12. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors. Pan Y; Wang Y; Bryant SH J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines. Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917 [TBL] [Abstract][Full Text] [Related]
14. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262 [TBL] [Abstract][Full Text] [Related]
15. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2. Mariano M; Hartmann RW; Engel M Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709 [TBL] [Abstract][Full Text] [Related]
16. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study. Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955 [TBL] [Abstract][Full Text] [Related]
17. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor. Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165 [TBL] [Abstract][Full Text] [Related]
19. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives. Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214 [TBL] [Abstract][Full Text] [Related]
20. Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4- Couly F; Harari M; Dubouilh-Benard C; Bailly L; Petit E; Diharce J; Bonnet P; Meijer L; Fruit C; Besson T Molecules; 2018 Aug; 23(9):. PubMed ID: 30158487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]